Read More About Medicines in Development for Children

America’s biopharmaceutical companies are researching 316 medicines to help meet the unique health care needs of children and adolescents. The medicines are currently in clinical trials or under review by the Food and Drug Administration (FDA).

PhRMA Statement on FDA Biomedical Innovation Report

Washington, D.C. (October 5, 2011) — Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John J. Castellani issued the following statement:
 
“We applaud Commissioner Hamburg and the FDA for the thoughtful and proactive approach to supporting health care innovation and improving patient access to new medicines and treatments outlined in the new report, Driving Biomedical Innovation. 
 

Antibiotics Conference Addresses Lack of New Drugs to Fight Deadly Superbugs

Washington, D.C. (September 22, 2011) — Leaders from government, industry, academia, medicine and science today will come together to discuss one of the most pressing health challenges we face: the rising incidence of drug-resistant bacteria and the lack of new antibiotics to fight them. The conference, "Reviving the Pipeline of Life-Saving Antibiotics: Exploring Solutions to Spur Innovation," is organized by the Pew Health Group, the Infectious Diseases Society of America (IDSA), and the Pharmaceutical Research and Manufacturers of America (PhRMA).

Nearly 200 Medicines in Development for Arthritis and Related Disorders, The Nation’s Most Common Cause of Disability

Washington, D.C. (July 13, 2011) — America’s biopharmaceutical research companies currently are developing 198 medicines to help the more than 50 million Americans that suffer from at least one of the many different musculoskeletal disorders, including arthritis. 

Backgrounder: Selected Medicines in Development for Musculoskeletal Disorders

Lupus affects at least 1.5 million Americans and 90 percent of lupus patients are women, according to the Lupus Foundation of America.  In lupus, the body develops antibodies (immune system proteins) that react against normal tissue, leading to inflammation, pain, tissue injury and major organ damage.  A new monoclonal antibody in development targets  B-cells that produce antibodies against the body’s own cells and tissue.  In lupus patients, these B-cells cause the immune system to turn on itself, resulting in inflammation and tissue damage.

John J. Castellani on Innovation

John J. Castellani
PhRMA President and CEO
delivered these remarks at the

N.Y. Bio Annual Meeting
Thursday, April 7, 2011

Thank you for that kind introduction and thanks to Kadmon Pharmaceuticals for sponsoring this lunch.

Discoverers 2011 Award: Januvia

R&D Investment by U.S. Biopharmaceutical Companies Reached Record Levels in 2010

Washington, D.C. (March 15, 2011) — Demonstrating a steady and ongoing commitment to innovative R&D, America’s biopharmaceutical research companies invested a record $67.4 billion last year in the research and development of new medicines and vaccines – an increase of $1.5 billion from 2009, according to analyses by the Pharmaceutical Research and Manufacturers of America (PhRMA) and Burrill & Company.

PhRMA Statement on Patent Reform

Washington, D.C. (March 9, 2011) — The Pharmaceutical Research and Manufacturers of America President and CEO John Castellani today released the following statement regarding the Senate passage of the patent reform bill:

PhRMA Statement on Ensuring Continued Medical Progress

Washington, D.C. (March 8, 2011) — A new report, “Emerging Biopharmaceutical Companies, Ensuring a Favorable Environment for Continued Innovation,” released today by the Pharmaceutical Research and Manufacturers of America (PhRMA), underscores the commitment of America’s biopharmaceutical research companies – of all sizes – to continued medical progress.

Pages

Subscribe to RSS - Innovation